Phase I trial of pod-intravaginal rings delivering antiretroviral agents for HIV-1 prevention: Rectal drug exposure from vaginal dosing with tenofovir disoproxil fumarate, emtricitabine, and maraviroc

BACKGROUND: Intravaginal rings (IVRs) can deliver antiretroviral (ARV) agents for HIV pre-exposure prophylaxis (PrEP), theoretically overcoming adherence concerns associated with frequent dosing. However, topical vaginal ARV drug delivery has not simultaneously led to sufficient rectal drug exposure...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:PLoS One
Main Authors: Vincent, Kathleen Listiak, Moss, John A., Marzinke, Mark A., Hendrix, Craig W., Anton, Peter A., Gunawardana, Manjula, Dawson, Lauren N., Olive, Trevelyn J., Pyles, Richard B., Baum, Marc M.
Format: Artigo
Jezik:Inglês
Izdano: Public Library of Science 2018
Teme:
Research Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6104940/
https://ncbi.nlm.nih.gov/pubmed/30133534
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0201952
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki